NASDAQ:CHRS Coherus BioSciences (CHRS) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free CHRS Stock Alerts $2.39 -0.03 (-1.24%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$2.36▼$2.5150-Day Range$2.02▼$2.8552-Week Range$1.43▼$8.65Volume2.09 million shsAverage Volume3.13 million shsMarket Capitalization$269.38 millionP/E RatioN/ADividend YieldN/APrice Target$9.29 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Coherus BioSciences alerts: Email Address Coherus BioSciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside288.5% Upside$9.29 Price TargetShort InterestBearish22.99% of Shares Sold ShortDividend StrengthN/ASustainability-1.08Upright™ Environmental ScoreNews Sentiment0.18Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.56) to $0.11 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.90 out of 5 starsMedical Sector220th out of 938 stocksBiological Products, Except Diagnostic Industry29th out of 148 stocks 3.4 Analyst's Opinion Consensus RatingCoherus BioSciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.29, Coherus BioSciences has a forecasted upside of 288.5% from its current price of $2.39.Amount of Analyst CoverageCoherus BioSciences has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted22.99% of the outstanding shares of Coherus BioSciences have been sold short.Short Interest Ratio / Days to CoverCoherus BioSciences has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Coherus BioSciences has recently increased by 7.07%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCoherus BioSciences does not currently pay a dividend.Dividend GrowthCoherus BioSciences does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCoherus BioSciences has received a 69.63% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Pegfilgrastim", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Coherus BioSciences is -1.08. Previous Next 1.8 News and Social Media Coverage News SentimentCoherus BioSciences has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Coherus BioSciences this week, compared to 3 articles on an average week.Search InterestOnly 22 people have searched for CHRS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows10 people have added Coherus BioSciences to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Coherus BioSciences insiders have not sold or bought any company stock.Percentage Held by Insiders10.99% of the stock of Coherus BioSciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions72.82% of the stock of Coherus BioSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Coherus BioSciences are expected to grow in the coming year, from ($0.56) to $0.11 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Coherus BioSciences is -0.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Coherus BioSciences is -0.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About Coherus BioSciences Stock (NASDAQ:CHRS)Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company provides UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; and CIMERLI, a biosimilar to Lucentis, a biosimilar product interchangeable with Lucentis for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization in the United States. It also offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; and Shanghai Junshi Biosciences Co., Ltd. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.Read More CHRS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CHRS Stock News HeadlinesMarch 21, 2024 | americanbankingnews.comCoherus BioSciences (NASDAQ:CHRS) PT Lowered to $11.00 at HC WainwrightMarch 21, 2024 | seekingalpha.comCoherus Biosciences: Dumping One Drug But Showing Promise With AnotherMarch 29, 2024 | Insiders Exposed (Ad)This consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.March 16, 2024 | finance.yahoo.comCoherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2023 Earnings Call TranscriptMarch 15, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Coherus Biosciences (CHRS) and Solid Biosciences (SLDB)March 15, 2024 | markets.businessinsider.comCoherus Biosciences: Strong Q4 Performance and Strategic Moves Merit Outperform RatingMarch 15, 2024 | finance.yahoo.comCoherus BioSciences Full Year 2023 Earnings: EPS Misses ExpectationsMarch 14, 2024 | fool.comWhy Coherus Biosciences Stock Tumbled on ThursdayMarch 29, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.March 14, 2024 | seekingalpha.comCoherus BioSciences, Inc. (CHRS) Q4 2023 Earnings Call TranscriptMarch 14, 2024 | finance.yahoo.comQ4 2023 Coherus BioSciences Inc Earnings CallMarch 13, 2024 | benzinga.comRecap: Coherus BioSciences Q4 EarningsMarch 13, 2024 | markets.businessinsider.comCoherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business UpdateMarch 13, 2024 | msn.comCoherus BioSciences Non-GAAP EPS of -$0.62 misses by $0.52, revenue of $91.5M beats by $1.07MMarch 13, 2024 | finance.yahoo.comCoherus BioSciences Inc (CHRS) Reports Growth in Net Revenue for Q4 and Full Year 2023 Despite ...March 13, 2024 | globenewswire.comCoherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business UpdateMarch 12, 2024 | msn.comCoherus BioSciences Q4 2023 Earnings PreviewMarch 6, 2024 | finance.yahoo.comIn the wake of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) latest US$49m market cap drop, institutional owners may be forced to take severe actionsMarch 5, 2024 | globenewswire.comCoherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024March 4, 2024 | finanznachrichten.deCoherus BioSciences, Inc.: Coherus Completes Divestiture of Ophthalmology FranchiseMarch 4, 2024 | globenewswire.comCoherus Completes Divestiture of Ophthalmology FranchiseFebruary 23, 2024 | globenewswire.comCoherus BioSciences Announces New Employment Inducement GrantsFebruary 21, 2024 | benzinga.comCoherus BioSciences Stock (NASDAQ:CHRS), Short Interest ReportFebruary 21, 2024 | finance.yahoo.comCoherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqvFebruary 21, 2024 | globenewswire.comCoherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqvFebruary 7, 2024 | investing.comCoherus BioSciences Inc (CHRS)February 6, 2024 | markets.businessinsider.comCoherus Biosciences Amends Loan Terms with BiopharmaSee More Headlines Receive CHRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Coherus BioSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/06/2023Today3/28/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CHRS CUSIPN/A CIK1512762 Webwww.coherus.com Phone(650) 649-3530FaxN/AEmployees299Year Founded2010Price Target and Rating Average Stock Price Target$9.29 High Stock Price Target$12.00 Low Stock Price Target$6.00 Potential Upside/Downside+288.5%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-237,890,000.00 Net Margins-92.48% Pretax Margin-92.62% Return on EquityN/A Return on Assets-44.16% Debt Debt-to-Equity RatioN/A Current Ratio1.43 Quick Ratio1.24 Sales & Book Value Annual Sales$257.24 million Price / Sales1.05 Cash FlowN/A Price / Cash FlowN/A Book Value($1.74) per share Price / Book-1.37Miscellaneous Outstanding Shares112,710,000Free Float100,327,000Market Cap$269.38 million OptionableOptionable Beta0.54 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Dennis M. Lanfear (Age 69)Chairman, President & CEO Comp: $1.79MMr. Bryan J. McMichael (Age 46)Interim CFO, Principal Financial and Accounting Officer, SVP-Accounting & Corporate Controller Mr. Richard L. HameisterChief Technical OfficerMs. Jami TaylorVice President of Investor RelationsCheston TurbyfillVice President of CommunicationsMr. Scott SaywellExecutive Vice President of Corporate DevelopmentMs. Rebecca Sunshine (Age 61)Chief Human Resources Officer Mr. Michael ChenSenior Vice President of Commercial Analytics & TradeMr. Paul Reider (Age 55)Chief Commercial Officer Dr. Theresa M. Lavallee Ph.D. (Age 58)Chief Development Officer & Chairman of Scientific Advisory Board More ExecutivesKey CompetitorsCentury TherapeuticsNASDAQ:IPSCSutro BiopharmaNASDAQ:STROGritstone bioNASDAQ:GRTSCompass TherapeuticsNASDAQ:CMPXScilexNASDAQ:SCLXView All CompetitorsInsiders & InstitutionsNomura Holdings Inc.Bought 47,290 shares on 3/27/2024Ownership: 0.061%Vanguard Group Inc.Bought 575,285 shares on 3/11/2024Ownership: 9.301%GSA Capital Partners LLPSold 72,703 shares on 2/16/2024Ownership: 0.022%Voya Investment Management LLCBought 36,072 shares on 2/15/2024Ownership: 0.089%Wolverine Trading LLCSold 11,800 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions CHRS Stock Analysis - Frequently Asked Questions Should I buy or sell Coherus BioSciences stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Coherus BioSciences in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CHRS shares. View CHRS analyst ratings or view top-rated stocks. What is Coherus BioSciences' stock price target for 2024? 6 Wall Street analysts have issued 12-month target prices for Coherus BioSciences' shares. Their CHRS share price targets range from $6.00 to $12.00. On average, they predict the company's share price to reach $9.29 in the next year. This suggests a possible upside of 288.5% from the stock's current price. View analysts price targets for CHRS or view top-rated stocks among Wall Street analysts. How have CHRS shares performed in 2024? Coherus BioSciences' stock was trading at $3.33 at the start of the year. Since then, CHRS stock has decreased by 28.2% and is now trading at $2.39. View the best growth stocks for 2024 here. Are investors shorting Coherus BioSciences? Coherus BioSciences saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 25,910,000 shares, an increase of 7.1% from the February 29th total of 24,200,000 shares. Based on an average daily volume of 5,770,000 shares, the short-interest ratio is currently 4.5 days. View Coherus BioSciences' Short Interest. When is Coherus BioSciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our CHRS earnings forecast. How were Coherus BioSciences' earnings last quarter? Coherus BioSciences, Inc. (NASDAQ:CHRS) released its quarterly earnings data on Monday, March, 6th. The biotechnology company reported ($0.76) earnings per share for the quarter, missing analysts' consensus estimates of ($0.64) by $0.12. The biotechnology company had revenue of $45.35 million for the quarter, compared to the consensus estimate of $45.72 million. During the same quarter in the previous year, the business posted ($0.60) EPS. What ETFs hold Coherus BioSciences' stock? ETFs with the largest weight of Coherus BioSciences (NASDAQ:CHRS) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA).First Trust Innovation Leaders ETF (ILDR). What guidance has Coherus BioSciences issued on next quarter's earnings? Coherus BioSciences issued an update on its FY 2023 earnings guidance on Wednesday, January, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $260.0 million-$260.0 million, compared to the consensus revenue estimate of $260.5 million. What is Dennis M. Lanfear's approval rating as Coherus BioSciences' CEO? 21 employees have rated Coherus BioSciences Chief Executive Officer Dennis M. Lanfear on Glassdoor.com. Dennis M. Lanfear has an approval rating of 95% among the company's employees. This puts Dennis M. Lanfear in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Coherus BioSciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus BioSciences investors own include Halozyme Therapeutics (HALO), Chembio Diagnostics (CEMI), Exelixis (EXEL), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Intelsat (I), Idera Pharmaceuticals (IDRA), Immunomedics (IMMU), Sangamo Therapeutics (SGMO) and Viking Therapeutics (VKTX). Who are Coherus BioSciences' major shareholders? Coherus BioSciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.30%), Vanguard Group Inc. (9.30%), Peregrine Capital Management LLC (0.98%), Charles Schwab Investment Management Inc. (0.69%), Nuveen Asset Management LLC (0.68%) and Cubist Systematic Strategies LLC (0.35%). Insiders that own company stock include Dennis M Lanfear, James Healy and Mcdavid Stilwell. View institutional ownership trends. How do I buy shares of Coherus BioSciences? Shares of CHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Coherus BioSciences have any subsidiaries? The following companies are subsidiares of Coherus BioSciences: Coherus Intermediate Corp, InteKrin, InteKrin Russia, and InteKrin Therapeutics Inc..Read More This page (NASDAQ:CHRS) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coherus BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.